Tradename | Company | Number | Date | Products |
---|---|---|---|---|
BRUKINSA | BeOne Medicines | N-218785 RX | 2025-06-10 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
brukinsa | New Drug Application | 2025-07-30 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
mantle-cell lymphoma | — | D020522 | C83.1 |
Expiration | Code | ||
---|---|---|---|
ZANUBRUTINIB, BRUKINSA, BEIGENE | |||
2030-01-19 | ODE-274 | ||
2028-09-14 | ODE-370 | ||
2028-08-31 | ODE-371 | ||
2026-11-14 | ODE-276 | ||
2026-01-19 | I-817 | ||
2024-11-14 | NCE | ||
2024-09-14 | I-874 | ||
2024-08-31 | I-871 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Zanubrutinib, Brukinsa, Beigene | |||
11786531 | 2043-01-19 | U-3715, U-3716, U-3717, U-3718, U-3719, U-3720 | |
11911386 | 2043-01-19 | U-3715, U-3716, U-3717, U-3718, U-3719, U-3720 | |
10927117 | 2037-08-15 | DS, DP | |
11591340 | 2037-08-15 | U-1745 , U-2145 , U-2537, U-2666 , U-3063 , U-3486 | |
11851437 | 2037-08-15 | DS, DP | |
11884674 | 2037-08-15 | U-1745, U-2145, U-2537, U-2666, U-3063, U-3486 | |
9447106 | 2034-04-22 | DS, DP | U-1745, U-2145, U-2537, U-2666, U-3063, U-3486 |
10570139 | 2034-04-22 | U-1745, U-2145, U-2537, U-2666, U-3063, U-3486 | |
11142528 | 2034-04-22 | DP | U-1745, U-2145, U-2537, U-2666, U-3063, U-3486 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 11 | 27 | 4 | 1 | 3 | 40 |
Waldenstrom macroglobulinemia | D008258 | — | C88.0 | 3 | 11 | 1 | 1 | 6 | 19 |
B-cell leukemia | D015448 | — | — | 1 | 1 | — | 1 | — | 2 |
Lymphatic diseases | D008206 | — | — | 1 | 1 | — | 1 | — | 2 |
Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lymphoma | D008223 | — | C85.9 | 12 | 61 | 5 | — | 10 | 83 |
B-cell lymphoma | D016393 | — | — | 11 | 36 | 4 | — | 2 | 48 |
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 7 | 36 | 3 | — | — | 44 |
Mantle-cell lymphoma | D020522 | — | C83.1 | 9 | 19 | 5 | — | 3 | 31 |
Follicular lymphoma | D008224 | — | C82 | 6 | 17 | 1 | — | 3 | 23 |
Lymphoid leukemia | D007945 | — | C91 | 4 | 14 | 2 | — | 1 | 19 |
B-cell lymphoma marginal zone | D018442 | — | C88.4 | 8 | 11 | 2 | — | 2 | 19 |
Leukemia | D007938 | — | C95 | 6 | 12 | 2 | — | — | 18 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 5 | 9 | 2 | — | 1 | 15 |
Neoplasms | D009369 | — | C80 | 8 | 5 | 1 | — | 1 | 11 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Recurrence | D012008 | — | — | 5 | 6 | — | — | — | 9 |
Healthy volunteers/patients | — | — | — | 8 | 1 | — | — | — | 9 |
Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | 5 | — | — | — | 5 |
Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | 4 | — | — | — | 4 |
Hematologic neoplasms | D019337 | — | — | 3 | 2 | — | — | — | 3 |
Hemolytic anemia autoimmune | D000744 | EFO_1001264 | D59.10 | — | 3 | — | — | — | 3 |
Syndrome | D013577 | — | — | 1 | 1 | — | — | — | 2 |
Interdigitating dendritic cell sarcoma | D054739 | — | C96.4 | 2 | 2 | — | — | — | 2 |
Paraproteinemias | D010265 | — | D47.2 | 1 | 2 | — | — | — | 2 |
Therapeutics | D013812 | — | — | — | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myelodysplastic syndromes | D009190 | — | D46 | 2 | — | — | — | — | 2 |
Myeloid leukemia acute | D015470 | — | C92.0 | 2 | — | — | — | — | 2 |
Myeloid leukemia | D007951 | — | C92 | 2 | — | — | — | — | 2 |
Reactive arthritis | D016918 | EFO_0007460 | M02.3 | 2 | — | — | — | — | 2 |
Preleukemia | D011289 | — | — | 1 | — | — | — | — | 1 |
Liver failure | D017093 | — | K72.9 | 1 | — | — | — | — | 1 |
Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | — | — | — | — | 1 |
T-cell lymphoma | D016399 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 2 | 2 |
Sudden death cardiac | D016757 | EFO_0004278 | — | — | — | — | — | 1 | 1 |
Heart arrest | D006323 | EFO_0009492 | I46 | — | — | — | — | 1 | 1 |
Supraventricular tachycardia | D013617 | — | I47.1 | — | — | — | — | 1 | 1 |
Psoriasis | D011565 | EFO_0000676 | L40 | — | — | — | — | 1 | 1 |
Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | — | — | — | 1 | 1 |
Eczema | D004485 | — | L30.9 | — | — | — | — | 1 | 1 |
Hidradenitis suppurativa | D017497 | — | L73.2 | — | — | — | — | 1 | 1 |
Pruritus | D011537 | — | L29 | — | — | — | — | 1 | 1 |
Mycosis fungoides | D009182 | — | C84.0 | — | — | — | — | 1 | 1 |
Drug common name | Zanubrutinib |
INN | zanubrutinib |
Description | Zanubrutinib, sold under the brand name Brukinsa, is an anticancer medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL). Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor. It is given by mouth.
|
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors Bruton's (Btk) inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1 |
PDB | — |
CAS-ID | 1651179-04-2 |
RxCUI | — |
ChEMBL ID | CHEMBL3936761 |
ChEBI ID | — |
PubChem CID | 135565884 |
DrugBank | DB15035 |
UNII ID | AG9MHG098Z (ChemIDplus, GSRS) |